Minerva Neurosciences Inc a clinical-stage biopharmaceutical company focused on the development and commercialization of certain proprietary product candidates to treat patients suffering from central nervous system (CNS) diseases. Its product candidate, Roluperidone, is in development for the treatment of negative symptoms in patients diagnosed with schizophrenia. Its Clinical-Stage Programs include Roluperidone and Seltorexant. The company's operations are organized into one operating and reportable segment focused on the development and commercialization of proprietary product candidates to treat patients suffering from CNS diseases.
Last trade$2.12
Day change-$0.08 (-3.64%)
Day range$2.03 – $2.34
Volume86,304
Market cap$110M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$109.64M
Price / earnings
—
Price / book
-1.12×
Price / sales
—
EV / sales
—
EV / EBITDA
-2.14×
Profitability
Earnings per share
-$5.95
Return on assets
-301.96%
Return on equity
304.3%
Dividend yield
0%
Liquidity and leverage
Debt / equity
-0×
Current ratio
33.02×
Quick ratio
33.02×
Cash ratio
8×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$31.4M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for NERV, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$0
$0
$0
$0
$0
$0
$0
$0
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$0
$0
$0
$0
$0
$0
$0
$0
Selling, general and administrative
$4.28M
$3.45M
$11.42M
$2.81M
$1.92M
$2.08M
$2.54M
$2.54M
Research and development
$5.16M
$7.19M
$5.25M
$2.17M
$925.38K
$1.3M
$1.36M
$1.98M
Total operating expenses
$9.43M
$10.64M
$16.67M
$4.98M
$2.84M
$3.37M
$3.9M
$4.52M
Operating income
-$9.43M
-$10.64M
-$16.67M
-$4.98M
-$2.84M
-$3.37M
-$3.9M
-$4.52M
Interest expense
$0
$0
$0
$0
$0
$0
$0
$0
Income before taxes
$100.75M
$17.47M
-$125.4M
-$283.67M
-$2.74M
-$3.26M
-$3.75M
-$4.27M
Income taxes
$0
$0
$0
$0
$0
$0
$0
$0
Net income
$100.75M
$17.47M
-$125.4M
-$283.67M
-$2.74M
-$3.26M
-$3.75M
-$4.27M
Net income attributable to common shareholders
$95.66M
$16.65M
-$125.4M
-$283.67M
-$2.74M
-$3.26M
-$3.75M
-$4.27M
EBITDA
-$9.43M
-$10.64M
-$16.67M
-$4.98M
-$2.84M
-$3.37M
-$3.9M
-$4.52M
Basic earnings per share
$1.94
$0.36
-$2.86
-$25.45
-$0.36
-$0.43
-$0.50
-$0.56
Diluted earnings per share
-$0.19
-$0.14
-$2.86
-$25.45
-$0.36
-$0.43
-$0.50
-$0.56
Recent news
Company coverage with links to the original publishers.
Minerva Neurosciences reported Q3 2026 financial results with R&D expenses of $5.2M (up from $0.9M YoY) driven by the ongoing Phase 3 C19 trial of roluperidone for schizophrenia negative symptoms. Topline efficacy data from Phase A is expected in 2H 2027. The company maintains $77M in cash and positions roluperidone as the only late-stage candidate targeting negative symptoms. A KOL event is scheduled for November 12, 2026.
Minerva Neurosciences announced participation in two upcoming investor conferences (Wells Fargo Healthcare Conference on September 8 and Cantor Global Healthcare Conference on September 9, 2026). The company is conducting a confirmatory Phase 3 trial of roluperidone for negative symptoms of schizophrenia, with topline efficacy data expected in the second half of 2027. The company has also established a Scientific Advisory Board of leading experts in psychiatry and neuroscience.
Minerva Neurosciences announced that CEO Remy Luthringer will present at The Stifel 2026 Virtual CNS Forum on March 18, 2026. The company is a clinical-stage biopharmaceutical firm focused on CNS disorder treatments, currently initiating a confirmatory Phase 3 trial with roluperidone for negative symptoms of schizophrenia.
Minerva Neurosciences reported FY2025 results with a net loss of $293.4 million (primarily due to $321.5 million in non-cash warrant and preferred stock issuance expenses). The company secured $80 million in gross proceeds from a private placement in October 2025 and plans to initiate a confirmatory Phase 3 trial for roluperidone for negative symptoms of schizophrenia in Q2 2026, with topline data expected in 2H 2027. Cash position improved to $82.4 million from $21.5 million year-over-year.
Minerva Neurosciences secured a $200 million funding agreement to support its Phase 3 trial for roluperidone, a drug targeting negative symptoms of schizophrenia. The funding includes immediate $80 million and potential additional tranches, with investors like Vivo Capital and Janus Henderson participating.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.